Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today (late breaking abstract #5500). This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed by a randomized phase 2 trial sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. 

The trial compared the activity of a combination of the drug olaparib (which blocks DNA repair) and the blood vessel inhibitor drug cediranib, vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit (the length of time during and after treatment that the cancer did not get worse) for the combination therapy over use of the single drug alone.

“The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,” said Joyce Liu, M.D., M.P.H., the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, Boston. “We are looking forward to further exploring this combination in ovarian cancer and potentially increasing effective treatment options for our patients with this cancer.”

Over 22,000 cases of ovarian cancer are diagnosed annually in the United States. Seventy-five percent of the cancers are classified as high-grade serous type, the women have more advanced disease at diagnosis, and their tumors are more aggressive. Of this high-grade type, about three-quarters of patients respond to initial treatment but nearly all will recur and need follow-up treatment. That treatment will be based on how the cancers have responded to previous therapies and are broken down into two categories based on patients’ responses to chemotherapy regimens that include platinum:

• Platinum-Sensitive – these are patients most likely to benefit from Poly ADP-Ribose Polymerase (PARP) inhibition.  PARP inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.
• Platinum-Resistant – these are patients whose disease recurred within six months of completion of conventional chemotherapy (using the drugs cisplatin or carboplatin) and are generally less responsive to subsequent treatments and have not responded as well to PARP inhibitors.  They are currently treated with non-platinum chemotherapy, single-agents, with or without addition of the blood vessel inhibitor drug called bevacizumab.

An anti-angiogenic agent, or blood vessel inhibitor called cediranib (which inhibits a protein known as VEGFR) and olaparib, a PARP inhibitor, are each clinically active in recurrent ovarian cancer. Preclinical laboratory studies suggest these agents add to and enhance the activity of each other, and an early phase 1 study showed that the combination of cediranib and olaparib was well-tolerated with minimal side effects. 

For this reason, 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 milligrams [mg] twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule form twice daily and 30 mg of cediranib by tablets once daily). The study arms were stratified by BRCA gene mutation status and receipt of prior anti-angiogenic therapy. The BRCA gene is one of the most commonly mutated genes in breast cancer.

Patients, whose median age was 58, were enrolled from October 2011 to June 2013.  As of March 2014, median progression-free survival was 9.2 months for olaparib and 17.7 months for the combination therapy, which is a significant advantage. The overall rate of toxicity was higher for patients on the combination therapy. Fatigue, diarrhea, and hypertension were the most common toxic effects, all of which were manageable.

“Of particular note is the fact that both drugs used in this trial are in pill form and could offer an alternative to intravenous chemotherapy,” said Percy Ivy, M.D., associate chief of NCI’s Investigational Drug Branch.  “Therefore, this combination therapy could be used anywhere in the world where patients can be safely monitored for the side-effects of olaparib and cediranib, such as diarrhea and hypertension.”

Based on these results, two phase 3 trials are being planned for platinum-sensitive and platinum-resistant ovarian cancer patients by one of NCI’s new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the  National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

This trial was funded by NCI and received supplementary funds from the Recovery Act. 

###

Reference: Liu, JF, et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the anti-angiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. NCT 01116648.  ASCO late breaking abstract #5500. http://www.cancer.gov/clinicaltrials/NCT01116648

The National Cancer Institute (NCI) leads the National Cancer Program and the NIH effort to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, is world-renowned for its leadership in adult and pediatric cancer treatment and research. Designated as a comprehensive cancer center by the National Cancer Institute, it is one of the largest recipients among independent hospitals of NCI and National Institutes of Health grant funding. For more information, go to www.dana-farber.org.